Summary

Celebrating visionary innovation in the discovery, design, and engineering of next-generation antibody therapeutics that push scientific boundaries and deliver transformative impact.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Demonstrated innovation in antibody discovery or engineering techniques.
• Evidence of impact on therapeutic development, such as improved efficacy, specificity, or manufacturability.
• Clear contribution to advancing the field through novel approaches or technologies.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

This award highlights pioneering advancements in antibody-drug conjugate (ADC) technology, including design, linker chemistry, payload development, toxicity optimisation or clinical translation that significantly advance the field.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Provide the name of your organisation or partnership and an overview of the ADC project, including its design, conjugation method, or payload innovation.
• Describe the evidence of improved therapeutic potential, safety, or efficacy, highlighting key progress or milestones achieved.
• Explain the impact of your ADC development on advancing towards clinical application and its potential to address unmet medical needs or transform healthcare.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Recognising significant contributions and breakthroughs in peptide therapeutic discovery, design, or development that have made a meaningful impact on science, medicine, or patient care.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Demonstrated innovation in peptide discovery, synthesis, or therapeutic application.
• Evidence of tangible impact on therapeutic development or clinical outcomes.
• Contribution to advancing the field of peptide therapeutics through novel approaches or technologies.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Honouring pioneering work at the cutting edge of oligonucleotide therapeutic discovery, design, and development, recognising those pushing the boundaries of science and innovation.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Demonstrated leadership in innovative oligonucleotide technology or therapeutic development.
• Evidence of groundbreaking advancements impacting therapeutic efficacy, delivery, or safety.
• Clear contribution to expanding the frontiers of oligonucleotide science and application.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Celebrating the most groundbreaking advances in cell and gene therapies, recognising projects, products, or platforms that are driving transformative impact for patients. It highlights innovation that pushes the boundaries of science, translation, and clinical application in one of the fastest-moving fields of medicine.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• A clear narrative demonstrating innovation and scientific or clinical impact in cell and/or gene therapy.
• Evidence of significant progress or a key milestone achieved within the past year.
• Demonstrated influence on the field, patient outcomes, or future therapeutic advancement.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Recognising groundbreaking therapies driving the future of immunotherapies discovery & development. It celebrates innovations that transform patient outcomes, introduce novel mechanisms, or deliver significant clinical impact.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• A compelling demonstration of innovative approaches and meaningful scientific or clinical impact in immunotherapy.
• Evidence of significant progress or a key milestone achieved within the past year.
• Demonstrated influence on the field, patient outcomes, or future therapeutic advancement.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Recognising excellence and innovation in platform technologies that enable efficient discovery, design, and development of both therapeutic and non-therapeutic vaccines.

Who Should Enter?

This Award is open to any platform or service provider that can demonstrate the following:

• Demonstrated innovation in vaccine discovery platform technologies or tools.
• Evidence of impact in accelerating research or improving vaccine candidates for therapeutic or preventive use.
• Proven success as a platform or service provider supporting vaccine development efforts.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Celebrating outstanding use of artificial intelligence to drive innovation, efficiency, or breakthrough results in biomedical research and development.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Demonstrated innovative application of AI technologies in biomedicine.
• Evidence of measurable impact on research, drug discovery, development, or patient care.
• Contribution to advancing AI integration within biomedical workflows or decision-making.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Honouring outstanding achievements in analytical method development, characterisation, and innovation that enable robust and precise evaluation of biologics, peptides, oligonucleotides, cell & gene therapies or complex therapeutics.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Development or application of novel analytical techniques or methods.
• Demonstrated impact on therapeutic characterisation, quality control, or process understanding.
• Contribution to advancing analytical science within biopharmaceutical development.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Recognising innovative and effective bioprocessing strategies that enhance efficiency, scalability, and quality in the development and manufacturing of biologics and advanced therapeutics.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Implementation of a novel or optimised bioprocessing approach demonstrating measurable improvements.
• Evidence of impact on process scalability, product quality, or cost-efficiency.
• Contribution to advancing bioprocess development or manufacturing practices.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Honouring a (CDMO) that demonstrates outstanding performance, innovation, and customer impact in biopharmaceutical manufacturing and development.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Evidence of innovative manufacturing or development solutions enhancing client outcomes.
• Demonstrated excellence in quality, scalability, and regulatory compliance.
• Strong track record of collaboration and impact across projects or partnerships.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Recognising a laboratory that has demonstrated exceptional scientific excellence, innovation, and impact in biomedical research and development.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• A compelling demonstration of innovative use or development of laboratory tools, techniques, or equipment that advance research capabilities.
• Evidence of significant progress, breakthrough experiments, or milestone achievements enabled by these tools or methodologies within the past year.
• Demonstrate influence on laboratory efficiency, reproducibility, team training, or broader scientific practice and standards.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Celebrating an exceptional partnership or team effort, that has driven significant scientific, clinical, or commercial progress in biomedicine.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Demonstrate clear and impactful outcomes resulting from the collaboration.
• Evidence of effective teamwork, cross-disciplinary or cross-sector partnership.
• Contribution to advancing innovation, speeding development, or improving patient outcomes.
• The partnership must be between pharma - biotech – academia – solution provider.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Celebrating outstanding efforts and innovations that promote sustainability, environmental responsibility, and green practices within the biomedical and life sciences sector.

Who Should Enter?

This Award is open to any pharma, biotech, solution provider company or academic / research institution that can demonstrate the following:

• Implementation of impactful sustainability initiatives or programs within biomedical research or operations.
• Demonstrate measurable environmental benefits or resource efficiencies.
• Commitment to advancing sustainable practices that can serve as a model for the industry.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Recognising an emerging start-up demonstrating exceptional innovation, growth potential, and impact in the biomedical or biotech space.

Who Should Enter?

This Award is open to any start-up company with fewer than 30 employees and operating for no more than 5 years that can demonstrate the following:

• Evidence of innovative technology, product, or approach with strong market potential.
• Demonstrate early achievements, milestones, or funding success within the past year.
• Clear vision and leadership poised to make significant contributions to the industry.

You must be a start-up company.

Entries should be based on activities undertaken between January 2024 and December 2025.

Summary

Honouring an individual or organisation championing diversity, equity, and inclusion within the biomedical and biotech sectors, driving meaningful cultural and systemic change.

Who Should Enter?

This Award is open to any individual or organisation regardless which sector you represent (pharma, biotech, start up, solution provider or academia).

You must demonstrate the following:

• Demonstrate leadership in promoting diversity, equity, and inclusion initiatives.
• Evidence of measurable impact on organisational culture, hiring, or community engagement.
• Commitment to fostering an inclusive environment that supports underrepresented groups in science and industry.

Entries should be based on activities undertaken between January 2024 and December 2025.